Alnylam Pharmaceuticals, Inc. (ALNY) shares fell 6.54 percent, declining $21.05 to $300.70 on Thursday even after the company reported a fourth-quarter profit compared with a loss a year earlier.
The stock opened at $314.42, down from a previous close of $321.75, and has traded between $298.00 and $315.51 during the session on the Nasdaq. The last reported bid was $300.00 for 100 shares, with the ask at $309.98 for 100 shares. Trading volume reached 552,594 shares, below the average volume of 1,494,936.
Alnylam shares have traded within a 52-week range of $205.87 to $495.55.
Net income for the quarter was $111.5 million, or $0.82 per share, compared with a loss of $83.8 million, or $0.65 per share, last year. On an adjusted basis, earnings per share increased to $1.25 from $0.06. Total revenues nearly doubled to $1.10 billion from $593.17 million, while net product revenues rose to $994.7 million from $450.8 million.
For 2026, the company projects total net product revenues in a range of $4.9 billion to $5.3 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.